Considering the different roles that STING could play in the outcome and progression of NAFLD, the aim of the current work is to provide new perspectives regarding the hepatic mRNA and protein expression of STING in a cohort of women presenting with morbid obesity (MO) and different NAFLD stages. This evidence concerns the gene STING1 and metabolic dysfunction-associated steatotic liver disease.